Detalles de la búsqueda
1.
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
Eur Heart J
; 2023 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36879424
2.
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1ß, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy.
Circulation
; 146(5): 372-379, 2022 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35762321
3.
Effect of alirocumab on cataracts in patients with acute coronary syndromes.
BMC Ophthalmol
; 23(1): 279, 2023 Jun 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37328736
4.
Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm.
Eur Heart J
; 43(18): 1715-1727, 2022 05 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35165703
5.
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
Circulation
; 144(22): 1750-1759, 2021 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34706555
6.
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
Circulation
; 144(23): 1845-1855, 2021 12 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34710343
7.
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
Circulation
; 143(1): 33-44, 2021 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33148016
8.
Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCI.
Am Heart J
; 249: 23-33, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35321823
9.
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.
Ann Intern Med
; 174(8): 1065-1072, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34152828
10.
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.
Circulation
; 141(5): 367-375, 2020 02 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31707829
11.
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
Eur Heart J
; 41(44): 4245-4255, 2020 11 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-33051646
12.
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.
Eur Heart J
; 41(24): 2248-2258, 2020 06 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31732742
13.
Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial.
Circulation
; 140(12): 1004-1014, 2019 09 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31362530
14.
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
Circulation
; 140(19): 1578-1589, 2019 11 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31475572
15.
Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
Stroke
; 51(7): 2066-2075, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32539675
16.
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.
Eur Heart J
; 45(13): 1173-1176, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38252107
17.
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.
Eur Heart J
; 40(33): 2801-2809, 2019 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31121022
18.
Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk.
Eur Heart J
; 39(24): 2255-2262, 2018 06 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-29394350
19.
Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials.
Eur Heart J
; 39(19): 1726-1735a, 2018 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29668889
20.
Effect of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease.
Diabetes Obes Metab
; 25(11): 3410-3414, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37427762